L1 Capital Global Opportunities Master Fund, Ltd. 13D and 13G filings for Aptevo Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-25 4:05 pm Purchase | 2025-04-21 | 13G | Aptevo Therapeutics Inc. APVO | L1 Capital Global Opportunities Master Fund, Ltd. | 1,169 7.590% | 400 (+51.99%) | Filing |
| 2025-04-25 4:01 pm Purchase | 2025-04-21 | 13G | Aptevo Therapeutics Inc. APVO | L1 Capital Global Opportunities Master Fund, Ltd. | 769 4.990% | 214 (+38.50%) | Filing |
| 2025-04-07 4:51 pm Purchase | 2025-04-02 | 13G | Aptevo Therapeutics Inc. APVO | L1 Capital Global Opportunities Master Fund, Ltd. | 556 6.210% | 556 (New Position) | Filing |